Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 14, 2026

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France –

GlobeNewsWire • May 12, 2026

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported better-than-expected first-quarter financial results on Tuesday.

Benzinga • May 6, 2026

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Bank of America Global Healthcare Conference on Wednesday, May 13 at 3:00 p.m.

GlobeNewsWire • May 6, 2026

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 5, 2026

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- First quarter 2026 net product revenue from global sales of IMCIVREE of $60.1 million -- -- IMCIVREE granted Marketing Authorization by European Commission for the treatment of obesity and control of hunger in patients with acquired hypothalamic obesity -- -- Japanese regulatory review of New Drug Application for setmelanotide to treat acquired hypothalamic obesity underway -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2026.

GlobeNewsWire • May 5, 2026

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.81 per share a year ago.

Zacks Investment Research • May 5, 2026

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pediatric patients with acquired hypothalamic obesity treated with setmelanotide -- BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the presentation of new data to be delivered by Rhythm and its partners at The Pediatric Endocrine Society (PES) Annual Meeting, taking place April 30-May 3, 2026, in San Francisco. “Acquired hypothalamic obesity is a complex disease that requires long-term management, particularly in pediatric patients,” said Jennifer Miller, M.D.

GlobeNewsWire • May 4, 2026

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --

GlobeNewsWire • May 1, 2026

Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 28, 2026